White House pulls Trump’s nomination for CDC director hours before confirmation hearing

White House pulls Trump’s nomination for CDC director hours before confirmation hearing


Former Congressman Dave Weldon addresses a small crowd in The Villages, Fla.

Brendan Farrington | AP

The White House has pulled President Donald Trump’s nominee to lead the Centers for Disease Control and Prevention, former Rep. Dave Weldon, the Senate’s Health committee confirmed Thursday.

The move came just hours before the former Florida lawmaker, a vaccine critic, was set to appear before the U.S. Senate Committee on Health, Education, Labor and Pensions for a confirmation hearing.

Axios first reported the decision on Thursday. Robert F. Kennedy, who leads the Department of Health and Human Services, said Weldon wasn’t ready for the role, Axios reported. HHS oversees the CDC and all other federal health agencies.

But Weldon’s views align closely with Kennedy, a notorious vaccine skeptic. Weldon, 71, has long questioned the safety of certain vaccines, promoting the false claim linking vaccines to autism. In 2006, Weldon appeared with parents who claimed that the CDC had covered up evidence tying vaccines to children developing autism.

The CDC will reportedly re-examine that link under Kennedy despite decades of research debunking it.

While in Congress, Weldon sponsored a bill that would transfer responsibility for vaccine safety away from the CDC. He claimed the agency had a conflict of interest because it purchases and promotes vaccines. The bill never made it past committees. 

Weldon is an internal medicine doctor who served in Congress for 14 years, from 1995 to 2009. 

This story is developing. Please check back for updates.



Source

Healthy Returns: What to expect from pharma at the JPM conference
Health

Healthy Returns: What to expect from pharma at the JPM conference

Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard Lutnick listen while U.S. President Donald Trump announces a deal with Eli Lilly and Novo Nordisk on to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White […]

Read More
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Health

A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year

Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600 […]

Read More
Patient advocacy groups urge U.S. court to halt overseas prescription drug operations
Health

Patient advocacy groups urge U.S. court to halt overseas prescription drug operations

In a photo illustration, prescription drugs are seen next to a pill bottle on July 23, 2024 in New York. Spencer Platt | Getty Images News | Getty Images A coalition of patient advocacy groups is urging a federal court to halt the practices of third-party companies that buy drugs from countries outside the FDA-regulated […]

Read More